Evidence map›Paper›PMID 39020347›Full record

ArticleCancer cell international2024

MiR-155 deficiency and hypoxia results in metabolism switch in the leukemic B-cells.

Elena Golovina, Tomas Heizer, Lenka Daumova, Martin Bajecny, Simona Fontana, Valentina Griggio, Rebecca Jones, Marta Coscia, Chiara Riganti, Karina Savvulidi Vargova

Abstract read
In one paragraph

Article in Cancer cell international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Elena GolovinaInstitute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
Tomas HeizerInstitute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
Lenka DaumovaInstitute Biocev, First Faculty of Medicine, Charles University, Vestec, Czech Republic.
Martin BajecnyInstitute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
Simona FontanaOncological Pharmacology Laboratory, Department of Oncology, University of Torino, Torino, Italy.
Valentina GriggioDepartment of Molecular Biotechnology and Health Sciences, University of Torino and Division of Hematology, A.O.U. Città Della Salute E Della Scienza Di Torino, Torino, Italy.
Rebecca JonesDepartment of Molecular Biotechnology and Health Sciences, University of Torino and Division of Hematology, A.O.U. Città Della Salute E Della Scienza Di Torino, Torino, Italy.
Marta CosciaDepartment of Molecular Biotechnology and Health Sciences, University of Torino and Division of Hematology, A.O.U. Città Della Salute E Della Scienza Di Torino, Torino, Italy.
Chiara RigantiOncological Pharmacology Laboratory, Department of Oncology, University of Torino, Torino, Italy.
Karina Savvulidi VargovaInstitute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic. vargova.mmbd@gmail.com.

Funding

Chiara Riganti IG21408Elena Golovina START/MED/089 and PRIMUS/17/MED/16Karina Savvulidi Vargova START/MED/089 and PRIMUS/17/MED/16Lenka Daumova START/MED/089Marta Coscia IG21408Martin Bajecny PROGRES Q26/LF1Rebecca Jones IG21408Simona Fontana IG21408Tomas Heizer START/MED/089Valentina Griggio IG21408
6 · The paper itself

Abstract

Hypoxia represents one of the key factors that stimulates the growth of leukemic cells in their niche. Leukemic cells in hypoxic conditions are forced to reprogram their original transcriptome, miRNome, and metabolome. How the coupling of microRNAs (miRNAs)/mRNAs helps to maintain or progress the leukemic status is still not fully described. MiRNAs regulate practically all biological processes within cells and play a crucial role in the development/progression of leukemia. In the present study, we aimed to uncover the impact of hsa-miR-155-5p (miR-155, MIR155HG) on the metabolism, proliferation, and mRNA/miRNA network of human chronic lymphocytic leukemia cells (CLL) in hypoxic conditions. As a model of CLL, we used the human MEC-1 cell line where we deleted mature miR-155 with CRISPR/Cas9. We determined that miR-155 deficiency in leukemic MEC-1 cells results in lower proliferation even in hypoxic conditions in comparison to MEC-1 control cells. Additionally, in MEC-1 miR-155 deficient cells we observed decreased number of populations of cells in S phase. The miR-155 deficiency under hypoxic conditions was accompanied by an increased apoptosis. We detected a stimulatory effect of miR-155 deficiency and hypoxia at the level of gene expression, seen in significant overexpression of EGLN1, GLUT1, GLUT3 in MEC-1 miR-155 deficient cells. MiR-155 deficiency and hypoxia resulted in increase of glucose and lactate uptake. Pyruvate, ETC and ATP were reduced. To conclude, miR-155 deficiency and hypoxia affects glucose and lactate metabolism by stimulating the expression of glucose transporters as GLUT1, GLUT3, and EGLN1 [Hypoxia-inducible factor prolyl hydroxylase 2 (HIF-PH2)] genes in the MEC-1 cells.

Indexed as

B-cellsCell viabilityCRISPR/Cas9Gene expressionHypoxiaLeukemiamiRNA

Identifiers

PMID39020347
PMCPMC11256420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.